Preclinical investigation of the pharmacokinetics, metabolism, and protein and red blood cell binding of DRDE-07: a prophylactic agent against sulphur mustard
暂无分享,去创建一个
[1] P. Verma,et al. HPLC DETERMINATION OF DRDE-07 IN MICE PLASMA: PROBABLE ANTIDOTE FOR SULFUR MUSTARD TOXICITY , 2013 .
[2] R. Vijayaraghavan,et al. Quantitative estimation of DRDE-07 in mice urine using ion-paired reversed-phase high-performance liquid chromatography , 2012 .
[3] Yong Zhang,et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..
[4] F. Lee,et al. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL , 2008, Cancer Chemotherapy and Pharmacology.
[5] K. P. Madhusudanan,et al. In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey—highlighting species similarities and differences , 2007, Biopharmaceutics & drug disposition.
[6] L. Granero,et al. General Treatment of the Enterohepatic Recirculation of Drugs and Its Influence on the Area Under the Plasma Level Curves, Bioavailability, and Clearance , 1992, Pharmaceutical Research.
[7] R. Vijayaraghavan,et al. In vivo protection by amifostine and DRDE-07 against sulphur mustard toxicity , 2002, Human & experimental toxicology.
[8] Younggil Kwon,et al. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.
[9] R. Tulsawani,et al. Protective effects of amifostine and its analogues on sulfur mustard toxicity in vitro and in vivo. , 2001, Toxicology and applied pharmacology.
[10] R. C. Malhotra,et al. Prophylactic efficacy of amifostine and its analogues against sulphur mustard toxicity. , 2001, Toxicology.
[11] Pravin Kumar,et al. Treatment for Sulphur Mustard Poisoning -A Review , 1998 .
[12] D. Hinshaw,et al. Sulfur mustard induces apoptosis and necrosis in endothelial cells. , 1996, Toxicology and applied pharmacology.
[13] R. Trapp,et al. A Commentary on the Chemical Weapons Convention , 1994 .
[14] L. Piddock,et al. Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. , 1993, The Journal of antimicrobial chemotherapy.
[15] A Z Momeni,et al. Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. , 1992, Archives of dermatology.
[16] W. Eisenmenger,et al. Clinical and morphological findings on mustard gas [bis(2-chloroethyl)sulfide] poisoning. , 1991, Journal of forensic sciences.
[17] M A Dunn,et al. Medical defense against blistering chemical warfare agents. , 1991 .
[18] B. Papirmeister,et al. Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications , 1991 .
[19] L. Piddock,et al. An investigation of the hydrophobicity of the quinolones. , 1986, The Journal of antimicrobial chemotherapy.
[20] William P. Purcell,et al. Strategy of drug design: A guide to biological activity , 1973 .
[21] Adrien Albert,et al. The determination of ionization constants : a laboratory manual , 1971 .